Polyneuron is proud to announce that – together with the University of Basel – we awarded grant of CHF 1.2M to advance novel treatments to support ABO-Incompatible transplants.
In other news
- 
                  
                  Uncategorized
 Polyneuron appoints Aled Williams as chief business officerWe are extremely pleased to welcome Aled Williams to Polyneuron… [read on] 
- 
                  
                  General
 Polyneuron extends Series A to CHF 36.5 millionPolyneuron announces a CHF 14 million extension of the Series… [read on] 
- 
                  
                  General
 Polyneuron's PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG NeuropathyPolyneuron is proud to announce that the U.S. Food and… [read on] 
- 
                  
                  General
 Polyneuron receives approval to begin clinical study with PN-1007 in anti-MAG neuropathyWe are very proud to have received our… [read on] 
- 
                  
                  General
 Polyneuron announces appointment of chief medical officerWe are extremely pleased to welcome Dr Debra Barker to… [read on] 
- 
                  
                  General
 Polyneuron annouces appointment of new ChairmanPolyneuron announces the appointment of Ben Machielse as Chairman of… [read on] 
- 
                  
                  Financing
 Polyneuron raises CHF 22.5 million in a major Series A financingPolyneuron raises CHF 22.5 million in an oversubscribed… [read on] 
- 
                  
                  Financing
 Completion of financing and team strengtheningPolyneuron announces the completion of a… [read on]